HYDROXYCARBAMINE: FROM AN OLD DRUG USED IN MALIGNANT HEMOPATHIES TO A CURRENT STANDARD IN SICKLE CELL DISEASE

While hydroxycarbamine (hydroxyurea, HU) has less and less indications in malignant hemopathies, it represents the only widely used drug which modifies sickle cell disease pathogenesis. Clinical experience with HU for patients with sickle cell disease has been accumulated over the past 25 years in W...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Giovanna Cannas, Solene Poutrel, Xavier Thomas
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	PAGEPress Publications 2017-02-01
Saila:	Mediterranean Journal of Hematology and Infectious Diseases
Gaiak:	hydroxyurea treatment sickle cell anemia clinical management hemoglobinopathies prognosis.
Sarrera elektronikoa:	http://www.mjhid.org/index.php/mjhid/article/view/2820
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!